Identification of Key Factors Associated with Early- and Late-Onset Ovarian Serous Cystadenocarcinoma

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136, e359–e386 (2015).
   PubMed Web of Science ®Google Scholar
• Gaba F , BlyussO, LiuXet al. Population study of ovarian cancer risk prediction for targeted screening and prevention. Cancers (Basel)12, E1241 (2020).
   PubMed Web of Science ®Google Scholar
• Staples JN , PeresLC, CamachoFet al. Cardiometabolic comorbidities and epithelial ovarian cancer risk among African–American women in the African–American Cancer Epidemiology Study (AACES). Gynecol. Oncol.158(1), 123–129 (.2020).
   PubMed Web of Science ®Google Scholar
• Davidson B . Biomarkers of drug resistance in ovarian cancer – an update. Expert. Rev. Mol. Diagn.19, 469–476 (2019).
   PubMed Web of Science ®Google Scholar
• Stewart C , RalyeaC, LockwoodS. Ovarian cancer: an integrated review. Semin. Oncol. Nurs.35, 151–156 (2019).
   PubMed Web of Science ®Google Scholar
• Gupta KK , GuptaVK, NaumannRW. Ovarian cancer: screening and future directions. Int. J. Gynecol. Cancer29, 195–200 (2019).
   PubMed Web of Science ®Google Scholar
• Reid BM , PermuthJB, SellersTA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med.14, 9–32 (2017).
   PubMed Web of Science ®Google Scholar
• Matulonis UA , SoodAK, FallowfieldLet al. Ovarian cancer. Nat. Rev. Dis. Primers2, 16061 (2016).
   PubMed Web of Science ®Google Scholar
• Bozas G , DimopoulosMA, KastritisEet al. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology70, 265–272 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshikawa N , KajiyamaH, MizunoMet al. Clinicopathologic features of epithelial ovarian carcinoma in younger vs older patients: analysis in Japanese women. J. Gynecol. Oncol.25, 118–123 (2014).
   PubMed Web of Science ®Google Scholar
• Cheng HY , ZengL, YeXet al. Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people. Chin. Med. J. (Engl.)133(11), 1285–1291 (.2020).
   PubMed Web of Science ®Google Scholar
• Elzakkers JCJ , vander Aa MA, van AltenaAMet al. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. Gynecol. Oncol.155, 213–219 (2019).
   PubMed Web of Science ®Google Scholar
• Chan JK , LoizziV, LinYGet al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet. Gynecol. 102, 156–161 (2003).
   PubMed Web of Science ®Google Scholar
• Harris MA , DeeganJI, LomaxJet al. The gene ontology project in 2008. Nucleic Acids Res.36, 440–444 (2008).
   PubMed Web of Science ®Google Scholar
• Consortium GO . The Gene Ontology (GO) project in 2006. Nucleic Acids Res.34, 322–326 (2006).
   PubMed Web of Science ®Google Scholar
• Consortium TGO Ashburner M , BallCAet al. Gene ontology: tool for the unification of biology. Nat. Genet.25, 25–29 (2000).
   PubMed Web of Science ®Google Scholar
• Kanehisa M , GotoS. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res.27, 29–34 (2000).
   Web of Science ®Google Scholar
• Armer JS , ClevengerL, DavisLZet al. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer124, 3401–3408 (2018).
   PubMed Web of Science ®Google Scholar
• Cuneo MG , SchrepfA, SlavichGMet al. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology84, 139–142 (2017).
   PubMed Web of Science ®Google Scholar
• Schrepf A , ThakerPH, GoodheartMJet al. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology53, 256–267 (2015).
   PubMed Web of Science ®Google Scholar
• Kulkarni JN , MistryRC, KamatMR, ChinoyR, LotlikarRG. Autonomous aldosterone-secreting ovarian tumor. Gynecol. Oncol.37, 284–289 (1990).
   PubMed Web of Science ®Google Scholar
• Todesco S , TerribileV, BorsattiA, ManteroF. Primary aldosteronism due to a malignant ovarian tumor. J. Clin. Endocrinol. Metab.41, 809–819 (1975).
   PubMed Web of Science ®Google Scholar
• Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer8, 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Liefers-Visser JAL , MeijeringRAM, ReynersAKL, vander Zee AGJ, de JongS. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat. Rev.60, 90–99 (2017).
   PubMed Web of Science ®Google Scholar
• Shibata K , KajiyamaH, MizokamiYet al. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol. Oncol.98, 11–18 (2005).
   PubMed Web of Science ®Google Scholar
• He Y , GuZ, ZhuQet al. CA125 over-release behavior following a 75-g oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer. Int. J. Cancer145, 1690–1700 (2019).
   PubMed Web of Science ®Google Scholar
• Li Y , FangY, LiuY, YangX. MicroRNAs in ovarian function and disorders. J. Ovarian Res.8, 51 (2015).
   PubMed Web of Science ®Google Scholar
• Trabert B , MichelsKA, AndersonGLet al. Circulating androgens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study. Int. J. Cancer145, 2051–2060 (2019).
   PubMed Web of Science ®Google Scholar
• Nieman KM , KennyHA, PenickaCVet al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med.17, 1498–1503 (2011).
   PubMed Web of Science ®Google Scholar
• Beaufort CM , HelmijrJC, PiskorzAMet al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One9, e103988 (2014).
   PubMed Web of Science ®Google Scholar
• Wang J , WuA, YangB, ZhuX, TengY, AiZ. Profiling and bioinformatics analyses reveal differential circular RNA expression in ovarian cancer. Gene724, 144150 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang W , PengP, OuX, ShenK, WuX. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. BMC Cancer19, 1095 (2019).
   PubMed Web of Science ®Google Scholar
• Xu Y , WangW, ChenJet al. High neuropilin and tolloid-like 1 expression associated with metastasis and poor survival in epithelial ovarian cancer via regulation of actin cytoskeleton. J. Cell. Mol. Med.24(16), 9114–9124 (.2020).
   PubMed Web of Science ®Google Scholar
• Del Porto F , CifaniN, ProiettaMet al. Lag3+ regulatory T lymphocytes in critical carotid artery stenosis. Clin. Exp. Med.19, 463–468 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang J , LiuW, XieTet al. Elevated LAG-3 on CD4+ T cells negatively correlates with neutralizing antibody response during HCV infection. Immunol. Lett.212, 46–52 (2019).
   PubMed Web of Science ®Google Scholar
• Feng X , TangR, ZhangRet al. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. J. Cell. Mol. Med.24(9), 5238–5248 (2020).
   PubMed Web of Science ®Google Scholar
• Tu L , GuanR, YangHet al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int. J. Cancer147, 423–439 (2020).
   PubMed Web of Science ®Google Scholar
• Norris EJ , ZhangQ, JonesWDet al. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. J. Pathol.248, 352–362 (2019).
   PubMed Web of Science ®Google Scholar
• Liu J , AgopiantzM, PouponJet al. Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer. Clin. Cancer Res.23, 6516–6528 (2017).
   PubMed Web of Science ®Google Scholar
• Corona RI , SeoJH, LinXet al. Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. Nat. Commun.11, 2020 (2020).
   PubMed Web of Science ®Google Scholar
• Dou YD , HuangT, WangQet al. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer. Biochem. Biophys. Res. Commun.496, 191–198 (2018).
   PubMed Web of Science ®Google Scholar
• Gu CL , ZhangZ, FanWSet al. Identification of microRNAs as potential biomarkers in ovarian endometriosis. Reprod. Sci.27(9), 1715–1723 (.2020).
   PubMed Web of Science ®Google Scholar
• Shen W , XieX, LiuM, WangL. Diagnostic value of lncRNA ROR in differentiating ovarian cancer patients. Clin. Lab.66, doi:10.7754/Clin.Lab.2019.191035 (.2020).
   Web of Science ®Google Scholar
• Zhou J , DongZN, QiuBQet al. CircRNA FGFR3 induces epithelial–mesenchymal transition of ovarian cancer by regulating miR–29a–3p/E2F1 axis. Aging (Albany NY)12(14), 14080–14091 (2020).
   PubMedGoogle Scholar
• Natanzon Y , GoodeEL, CunninghamJM. Epigenetics in ovarian cancer. Semin. Cancer Biol.51, 160–169 (2018).
   PubMed Web of Science ®Google Scholar
• Mohamed NE , HayT, ReedKR, SmalleyMJ, ClarkeAR. APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression. BMC Cancer19, 677 (2019).
   PubMed Web of Science ®Google Scholar